Rheumatoid arthritis: frequency of hospitalization and evaluation of economic burden

Ciocci, A; Buratti, Laura; Coari, Giulio; Franco, Manuela Di; Iagnocco, Annamaria; Mauceri, M.; Serio, Alessandra

doi:10.4081/reumatismo.2001.215

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Frequent RA hospital separation was defined as two or more separations for RA diagnostic codes (primary or secondary) in a calendar year [ 25 ]. The potential associated factors assessed were sex, age, and geographic locations as commonly published in the literature [ 5 , 26 , 27 ].…”

Section: Methodsmentioning

confidence: 99%

The prevalence of rheumatoid arthritis in Western Australia

et al. 2022

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis, but the prevalence in Australia is unknown. We estimated RA period prevalence and identified factors associated with frequent RA hospitalisations, using linked administrative health and state-specific Australian Pharmaceutical Benefits Scheme (PBS) datasets in Western Australia (WA) from 1995 to 2014. Methods This was a longitudinal population-based cohort study using two independent datasets to identify prevalent RA patients. RA prevalence was calculated per 1000 hospital separations and biological therapy users. RA patients were identified in the WA linked health dataset using ICD codes 714.0–714.9 and M05.00–M06.99. Dispensing data on biological therapy for RA were obtained from PBS records and converted to defined daily doses /1000 population/day. Multivariable logistic regression was used to analyse factors associated with frequent RA hospitalisations (> 2/year), controlling for sex, age, and geographic locations. Potential interactions were assessed using logistic regression in a stepwise approach. Results A total of 17,125 RA patients had 50,353 hospital separations between 1995 and 2014, averaging three hospitalisations per patient over 20 years. The RA period prevalence was 3.4 per 1000 separations (0.34%; 95% CI 0.33–0.34), while the RA period prevalence based on biological therapy use was 0.36% (95% CI 0.35–0.37). The corrected RA prevalence based on biological therapy usage was 0.36% (95% CI 0.35–0.37) for the 2005–2009 and increased to 0.72% (95% CI 0.70–0.74) in 2010–2014 period. Associated factors for frequent RA hospitalisations were being female [1.21 (95% CI 1.15–1.26)], aged 60–69 years [4.45 (95% CI 3.74–5.30)], living in rural areas [1.12 (95% CI 1.02–1.24)]. The odd ratio of interaction between these associated factors was 1.34 (95% CI 1.16–1.55). Conclusion The minimal prevalence of RA in Western Australia is 0.34–0.36%, which falls within the literature range. Older female RA patients in rural were more likely to be hospitalised, suggesting unmet primary care for needs.

show abstract

Section: Methodsmentioning

confidence: 99%

The prevalence of rheumatoid arthritis in Western Australia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Nel 2001 in Italia i costi diretti e indiretti associati all' AR erano stati stimati intorno a 1.600 milioni di Euro l'anno [52]. Nel 2002 un altro studio italiano ha analizzato i costi di malattia dell' AR in base alla gravità della malattia [53].…”

Section: Costo DI Malattia In Italiaunclassified

Pharmacologic and economic differentiation of drugs for RA in Italy

Berto¹,

Eandi

2012

RHC

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic, progressive and degenerative illness, which affects about 0.5% of the adult population with significant social costs. In Italy there are approximately 300,000 people with RA, with twice as many women than men. RA causes progressive deformity and disability and is associated with numerous co-morbid conditions that reduce the life expectancy of 5-10 years. The costs of RA have a serious impact on the entire community, especially in terms of disability, hospitalization and medical care. In Italy has been estimated that cost of illness could reach about 1,600 million euros, of which over two thirds are represented by indirect costs. The treatment of RA is evolving and the introduction of biological drugs has resulted in a significant progress in terms of therapeutic possibilities. Etanercept, the only soluble receptor of TNF-alfa currently approved appears to be cost-effective and it is recommended by major guidelines for the treatment of RA.

http://dx.doi.org/10.7175/rhc.v3i3.201

show abstract

Rheumatoid arthritis: frequency of hospitalization and evaluation of economic burden

Cited by 2 publications

References 0 publications

The prevalence of rheumatoid arthritis in Western Australia

The prevalence of rheumatoid arthritis in Western Australia

Pharmacologic and economic differentiation of drugs for RA in Italy

Contact Info

Product

Resources

About